

GEORGIA MEDICAID FEE-FOR-SERVICE METHOTREXATE PA SUMMARY

Preferred	Non-Preferred
Methotrexate injection, tablets generic	Jylamvo (methotrexate oral solution) Otrexup (methotrexate auto-injector) Rasuvo (methotrexate auto-injector) Reditrex (methotrexate prefilled syringe) Xatmep (methotrexate oral solution)

LENGTH OF AUTHORIZATION: 1 year

PA CRITERIA:

Jylamvo

- ❖ Approvable for members 18 years of age or older with a diagnosis of acute lymphoblastic leukemia (ALL) or relapsed or refractory non-Hodgkin lymphoma when used as a component of a combination chemotherapy maintenance regimen.
- ❖ Approvable for members 18 years of age or older with a diagnosis of mycosis fungoides or severe psoriasis.
- ❖ Approvable for members 18 years of age or older with a diagnosis of rheumatoid arthritis (RA) who have experienced inadequate response, allergies, contraindications, drug-drug interactions or intolerable side effects with non-steroidal drugs (NSAIDs).

AND

❖ For all diagnoses, members must not be able to swallow solid oral dosage formulations (i.e., tablets, capsules).

Otrexup, Rasuvo and Reditrex

- ❖ Approvable for members 2 years of age or older with a diagnosis of severe, active rheumatoid arthritis (RA) or severe, active polyarticular juvenile idiopathic arthritis (pJIA) who have experienced inadequate response, allergies, contraindications, drug-drug interactions or intolerable side effects with non-steroidal drugs (NSAIDs) and have experienced inadequate response or intolerable side effect with oral methotrexate.
- ❖ Approvable for members 18 years of age or older with a diagnosis of severe, recalcitrant, disabling psoriasis who have experienced inadequate response or intolerable side effect with oral methotrexate.

AND

For all diagnoses, member must be unable to receive generic injectable methotrexate administered in a physician's office due to transportation difficulties.



Xatmep

- ❖ Approvable for members 2 to 17 years of age with a diagnosis of acute lymphoblastic leukemia (ALL) when used as a component of a combination chemotherapy maintenance regimen.
- ❖ Approvable for members 2 to 17 years of age with a diagnosis of active polyarticular juvenile idiopathic arthritis (pJIA) who have experienced inadequate response, allergies, contraindications, drug-drug interactions or intolerable side effects with non-steroidal drugs (NSAIDs).

AND

❖ For all diagnoses, members 12-17 years of age must not be able to swallow solid oral dosage formulations (i.e., tablets, capsules).

EXCEPTIONS:

- Exceptions to these conditions of coverage are considered through the prior authorization process.
- ❖ The Prior Authorization process may be initiated by calling OptumRx at 1-866-525-5827.

PREFERRED DRUG LIST:

❖ For online access to the Preferred Drug List (PDL), please go to http://dch.georgia.gov/preferred-drug-lists.

PA and APPEAL PROCESS:

❖ For online access to the PA process, please go to www.dch.georgia.gov/prior-authorization-process-and-criteria and click on Prior Authorization (PA) Request Process Guide.

OUANTITY LEVEL LIMITATIONS:

❖ For online access to the current Quantity Level Limits (QLL), please go to www.mmis.georgia.gov/portal, highlight Provider Information and click on Provider Manuals. Scroll to the page with Pharmacy Services and select that manual.